Jaguar Health Expands Neonorm Franchise with Plant-Based, Non-Prescription Canine Gut Health Product
Jaguar Health will launch Neonorm Dog, a plant-based, non-prescription supplement that supports normal stool formation, gut hydration and bowel health in dogs. The addition expands the Neonorm franchise beyond foals and calves and follows positive trial results for the prescription product Canalevia-CA1 in canine chemotherapy-induced diarrhea.
1. Launch of Neonorm Dog
Jaguar Health announced the planned introduction of Neonorm Dog, a non-prescription, plant-based supplement designed to support normal stool formation, gut hydration and bowel health in companion dogs. Final packaging and labeling are underway ahead of distribution through select online and animal health retail channels.
2. Expansion of the Neonorm Franchise
This launch extends the existing Neonorm lineup, which includes Neonorm Foal and Neonorm Calf for pre-weaned horses and cattle, leveraging a standardized botanical extract from the sustainably harvested Croton lechleri tree that acts locally in the gut to promote hydration and stool quality.
3. Strategic Companion Animal Focus
By entering the canine market, Jaguar aims to tap into one of the largest companion animal populations in the U.S. and Europe, targeting pet owners and veterinarians seeking plant-based, non-antibiotic digestive health solutions, and enhancing brand awareness for the Neonorm platform.
4. Animal Health Pipeline and FDA Progress
Jaguar’s prescription therapy Canalevia-CA1 holds conditional FDA approval for chemotherapy-induced diarrhea in dogs, and recent topline trial data demonstrated statistically significant effectiveness, supporting the company’s pursuit of full regulatory approval and broader veterinary adoption.